News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
431,969 Results
Type
Article (18870)
Company Profile (75)
Press Release (413023)
Multimedia
Podcasts (93)
Webinars (13)
Section
Business (156802)
Career Advice (875)
Deals (24875)
Drug Delivery (106)
Drug Development (48156)
Employer Resources (73)
FDA (8873)
Job Trends (8775)
News (222321)
Policy (18876)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (7)
40 Under 40 (1)
Academia (736)
Accelerated approval (36)
ADA (18)
Adcomms (13)
Allergies (133)
Alliances (31593)
ALS (117)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (282)
Approvals (9381)
Artificial intelligence (455)
ASCO (151)
Autoimmune disease (186)
Automation (35)
Bankruptcy (216)
Belgium (11)
Best Places to Work (6220)
BIO (35)
Biologics (32)
BIOSECURE Act (10)
Biosimilars (208)
BioSpace Insights (80)
Biotechnology (41)
Bispecific (3)
Bladder cancer (100)
Brain cancer (51)
Breast cancer (337)
Cancer (2957)
Cardiovascular disease (316)
Career advice (774)
Career pathing (21)
CAR-T (149)
CDC (11)
CDMO (100)
Celiac Disease (3)
Cell therapy (406)
Cervical cancer (29)
Clinical research (43050)
Collaboration (1421)
Commercialization (23)
Company closure (3)
Compensation (908)
Complete response letters (59)
COVID-19 (1028)
CRISPR (78)
CRO (1)
C-suite (1128)
Cystic fibrosis (87)
Data (4487)
Decentralized trials (2)
Denatured (20)
Depression (85)
Dermatology (75)
Diabetes (304)
Diagnostics (3289)
Digital health (28)
Diversity (5)
Diversity, equity & inclusion (20)
Drug discovery (244)
Drug pricing (145)
Drug shortages (17)
Duchenne muscular dystrophy (163)
Earnings (63068)
Editorial (34)
Employer branding (14)
Employer resources (71)
Events (68187)
Executive appointments (958)
Eye disease (3)
FDA (11181)
Fibrodysplasia Ossificans Progressiva (10)
Fragile X (1)
Friedreich's ataxia (13)
Frontotemporal dementia (17)
Funding (998)
Gene editing (121)
Generative AI (41)
Gene therapy (361)
GLP-1 (638)
Government (1819)
Grass and pollen (4)
Guidances (287)
Healthcare (7671)
Hematology (101)
HIV (36)
Huntington's disease (31)
Idiopathic pulmonary fibrosis (6)
IgA nephropathy (84)
Immunology and inflammation (158)
Immuno-oncology (57)
Indications (154)
Infectious disease (1172)
Inflammatory bowel disease (116)
Inflation Reduction Act (7)
Influenza (43)
Intellectual property (185)
Interviews (109)
IPO (11177)
IRA (38)
Job creations (2756)
Job search strategy (687)
JPM (35)
Kidney cancer (20)
Kidney disease (61)
Labor market (57)
Layoffs (323)
Leadership (23)
Legal (5099)
Licensing (52)
Liver cancer (47)
Longevity (21)
Lung cancer (392)
Lung diease (6)
Lymphoma (258)
Machine learning (26)
Management (24)
Manufacturing (886)
Marketing (14)
MASH (137)
Medical affairs (4)
Medical device (4854)
Medtech (4932)
Mergers & acquisitions (14631)
Metabolic disorders (887)
mRNA (102)
Multiple sclerosis (92)
Multispecific (2)
NASH (18)
Netherlands (8)
Neurodegenerative disease (203)
Neuropsychiatric disorders (66)
Neuroscience (1706)
Neurotech (1)
NextGen: Class of 2026 (2869)
Non-profit (1217)
Now hiring (35)
Obesity (424)
Opinion (196)
Ovarian cancer (98)
Pain (174)
Pancreatic cancer (143)
Parkinson's disease (175)
Partnered (20)
Patents (383)
Patient advocacy (1)
Patient recruitment (344)
Patient selection (27)
Peanut (27)
People (43353)
Peptides (12)
Pharmaceutical (36)
Pharmacy benefit managers (21)
Phase 1 (11889)
Phase 2 (18454)
Phase 3 (15789)
Pipeline (7294)
Policy (187)
Postmarket research (1735)
Preclinical (4766)
Press Release (72)
Prostate cancer (171)
Psychedelics (36)
Radioligand (1)
Radiopharmaceuticals (283)
Rare diseases (763)
Real estate (3833)
Recruiting (29)
Regenerative medicine (5)
Regulatory (15325)
Reports (34)
Research institute (816)
Resumes & cover letters (127)
Rett syndrome (44)
RNA editing (14)
RSV (28)
Schizophrenia (132)
Series A (193)
Series B (132)
Service/supplier (1)
Sickle cell disease (71)
Special edition (17)
Spinal muscular atrophy (133)
Sponsored (20)
Startups (2267)
State (2)
Stem cells (2)
Stomach cancer (9)
Substance use disorders (7)
Supply chain (91)
Switzerland (1)
Tariffs (78)
The Weekly (71)
Vaccines (404)
Venture capital (83)
Weight loss (233)
Wet AMD (1)
Women's health (79)
Worklife (5)
Date
Today (1)
Last 7 days (313)
Last 30 days (1251)
Last 365 days (16625)
2026 (13202)
2025 (16555)
2024 (19553)
2023 (22847)
2022 (31114)
2021 (32605)
2020 (30654)
2019 (23691)
2018 (18365)
2017 (19767)
2016 (18572)
2015 (22506)
2014 (18507)
2013 (15594)
2012 (16776)
2011 (17482)
2010 (16507)
Location
Africa (456)
Alabama (43)
Alaska (3)
Arizona (152)
Arkansas (5)
Asia (28163)
Australia (3761)
California (7871)
Canada (2720)
China (1055)
Colorado (360)
Connecticut (377)
Delaware (248)
Europe (58014)
Florida (1376)
Georgia (172)
Hawaii (2)
Idaho (30)
Illinois (678)
India (116)
Indiana (423)
Iowa (12)
Japan (532)
Kansas (104)
Kentucky (35)
Louisiana (20)
Maine (63)
Maryland (820)
Massachusetts (6290)
Michigan (157)
Minnesota (394)
Mississippi (2)
Missouri (74)
Montana (19)
Nebraska (15)
Nevada (79)
New Hampshire (26)
New Jersey (2794)
New Mexico (12)
New York (2036)
North Carolina (1180)
North Dakota (7)
Northern California (4034)
Ohio (247)
Oklahoma (9)
Oregon (22)
Pennsylvania (1501)
Puerto Rico (24)
Rhode Island (26)
South America (679)
South Carolina (29)
Southern California (3222)
Tennessee (151)
Texas (1213)
United States (29181)
Utah (208)
Vermont (1)
Virginia (304)
Washington D.C. (47)
Washington State (623)
West Virginia (3)
Wisconsin (117)
Wyoming (2)
431,969 Results for "novartis pharmaceuticals corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
September 23, 2026
·
2 min read
·
Tristan Manalac
Clinical research
Novartis drags peers down with triple asset stumble
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
September 11, 2026
·
1 min read
·
Annalee Armstrong
Manufacturing
3 steps for taking on Novartis in radiopharma: Curium up first
To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
September 29, 2026
·
4 min read
·
Nick Paul Taylor
Opinion
How Abogen went from COVID hype to a $7.8B Novartis deal
After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.
October 9, 2026
·
5 min read
·
Lewis Zhang
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
Novartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.
September 17, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for their recently approved IgAN therapies Fabhalta and Trutakna.
July 20, 2026
·
2 min read
·
Tristan Manalac
Editorial
After Novartis’ devastating M&A losses, long live the executive willing to try
Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
September 17, 2026
·
2 min read
·
Annalee Armstrong
Cardiovascular disease
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.
September 8, 2026
·
2 min read
·
Tristan Manalac
Deals
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.
October 2, 2026
·
2 min read
·
Tristan Manalac
C-suite
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
September 11, 2026
·
5 min read
·
Nick Paul Taylor
1 of 43,197
Next
